Articles
Clinical Monographs
In-depth, citation-backed writing on clinical monographs. · 15 articles in Clinical Monographs
What Does 2026 Research Reveal About Current Trends in Semaglutide Therapy and Strategies to Improve Its Oral Bioavailability?
A 2026 review by Nayak et al. in Expert Opinion on Drug Delivery identifies oral bioavailability as semaglutide's central unresolved limitation, with approved oral Rybelsus® achieving only ~0.4–1% absolute bioavailability via the SNAC mechanism. The review catalogues novel strategies — lipid nanoparticles, SNEDDS, mucoadhesive polymers, and ionic liquid complexation — designed to overcome gastric acid degradation and first-pass proteolysis.
Can Avexitide Reduce Post-Bariatric Hypoglycemia Through GLP-1 Receptor Antagonism, and What Did the 2026 Phase 3 LUCIDITY Trial Show?
Yes. Avexitide — a competitive GLP-1 receptor antagonist derived from the truncated exendin-(9-39) peptide — reduces post-bariatric hypoglycemia by blocking the exaggerated postprandial GLP-1 signal driving pathological insulin secretion after Roux-en-Y gastric bypass. The 78-participant phase 3 LUCIDITY trial (August 2026) met its FDA-agreed primary endpoint: a 55% reduction in composite Level 2 and Level 3 events versus placebo (p=0.000003).
Why Did the EVOKE Trial Design Structurally Fail to Test Semaglutide's Neuroprotective Hypothesis in 2026, and What Would a Valid Prevention Trial Require?
The 2026 Alhowail review in Frontiers in Aging Neuroscience concludes that the EVOKE Phase 3 trials were structurally mismatched to semaglutide's neuroprotective hypothesis across three dimensions: oral delivery producing CNS underexposure, population selection in patients with established pathology, and a clinical endpoint insensitive to metabolic stabilisation. A valid prevention trial requires subcutaneous dosing, cognitively normal at-risk participants, and biomarker-primary endpoints.
Does the Epidemiological Signal for Semaglutide and Dementia Risk Survive Methodological Scrutiny in 2026?
The epidemiological signal is consistent but not causally established. Across six independent cohort studies through 2026, semaglutide users with type 2 diabetes show 40 to 70 percent lower dementia incidence versus comparator antidiabetic agents. Active-comparator designs reduce but cannot eliminate confounding; the negative EVOKE Phase 3 trials introduce an interpretive tension the 2026 Alhowail review frames as a population-timing mismatch.
How Does Semaglutide's GLP-1R/SIRT1 Axis Address Brain Insulin Resistance as a Metabolic Root of Cognitive Decline in 2026?
The 2026 Alhowail review in Frontiers in Aging Neuroscience frames brain insulin resistance — not amyloid burden alone — as the upstream metabolic lesion that semaglutide's GLP-1R/SIRT1/GLUT4 axis is best positioned to correct. Preclinical data show restored cerebral glucose uptake, suppressed NLRP3 inflammasome activation, and attenuated tau hyperphosphorylation, but human prevention trials in at-risk populations remain the critical missing evidence.
Does CRB-913's Peripherally Restricted CB1 Inverse Agonism Offer a Clinically Meaningful Non-Incretin Obesity Mechanism in 2026?
Yes, with important caveats. CRB-913's 2026 CANYON-1 Phase 1b readout showed 5% placebo-adjusted weight loss at 60 mg over 12 weeks with a clean neuropsychiatric safety profile, establishing peripheral CB1 inverse agonism as a mechanistically distinct, non-incretin obesity pathway. The mechanism operates through leptin-resistance reversal and direct adipose and hepatic lipid suppression, positioning it as a complement to GLP-1/GIP therapies.
Can TS-104, a First-in-Class Peptide-Drug Conjugate, Achieve a Tolerable Dose-Escalation Profile in Solid Tumors Without Dose-Limiting Toxicity in 2026?
TS-104 is a first-in-class, fully synthetic peptide-drug conjugate that couples a polyspecific integrin-binding peptide (PIP) to the cytotoxin MMAE. Whether it achieves a tolerable dose-escalation profile without dose-limiting toxicity in humans remains open: FDA IND clearance was granted in September 2026, and the first-in-human Phase 1 trial (NCT07814248) is now enrolling patients with advanced solid tumors.
What Does 2026 Research Reveal About Semaglutide's Neuroprotective Potential, and Why Did the EVOKE Trials Fail to Confirm It?
A 2026 review in Frontiers in Aging Neuroscience (Alhowail) concludes that semaglutide's neuroprotective mechanisms — GLP-1 receptor activation in the brain, reduced neuroinflammation, improved cerebral glucose metabolism, and attenuation of amyloid-β and tau pathology — are well-supported preclinically. The EVOKE and EVOKE+ Phase 3 trials found no cognitive benefit in established Alzheimer's disease, shifting the hypothesis toward early prevention.
How Does Mazdutide's Dose-Response Relationship in the 2026 U.S. Phase 2 Trial Inform Phase 3 Dose Selection for Obesity?
The 2026 United States phase 2 mazdutide trial produced placebo-corrected weight reductions of 6%, 14%, and 17% at week 32 across 3–6 mg, 10 mg, and 16 mg arms. The dose-response curve was monotonic but non-linear. The 10 mg arm captured most of the efficacy gain with tolerability burden comparable to approved agents, making it the leading phase 3 candidate.
What Did the First U.S. Phase 2 Mazdutide Trial Show for Weight Loss, HbA1c, and Tolerability in 2026?
The first United States phase 2 trial of mazdutide reported dose-dependent weight reductions of up to 18% at 32 weeks in adults with obesity or overweight. Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist. All active doses produced significant HbA1c decreases versus placebo. Gastrointestinal adverse events were the dominant tolerability signal with discontinuation rates reaching 20% at 16 mg.
Does Retatrutide Improve Liver Disease Outcomes Beyond Weight Loss in 2026 Preclinical and Translational Evidence?
Preclinical and translational data through 2026 indicate that retatrutide reduces hepatic steatosis and inflammation through mechanisms extending beyond caloric-deficit-driven weight loss. Glucagon receptor co-agonism drives direct hepatic fatty acid oxidation and suppresses de novo lipogenesis, while GLP-1 receptor activity attenuates hepatic inflammation via NF-κB inhibition. Whether these weight-independent pathways translate to durable fibrosis regression in humans remains an open question.
Does the 2026 BPC-157 Hamstring Strain RCT (NCT07437547) Use MRI Injury Volume and Return-to-Sport as Co-Primary Endpoints?
Yes. NCT07437547, a Phase 2 randomised, double-blind, placebo-controlled trial currently recruiting in 2026, designates two co-primary endpoints: time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14. The trial enrols 120 adults with MRI-confirmed acute grade II hamstring strain and administers subcutaneous BPC-157 or placebo once daily for 14 days alongside a standardised rehabilitation programme.